68th Day Of Lockdown

Maharashtra65168280812197 Tamil Nadu2024611313157 Delhi173877846398 Gujarat1635692321007 Rajasthan83654855184 Madhya Pradesh78914444343 Uttar Pradesh77014651213 West Bengal48131775302 Andhra Pradesh3461228960 Bihar3359120915 Karnataka292299749 Telangana2499141277 Jammu and Kashmir234190828 Punjab2197194942 Odisha17239779 Haryana172194019 Kerala120957510 Assam9361044 Uttarakhand493794 Jharkhand4621914 Chhatisgarh4471021 Chandigarh2891994 Tripura2711720 Himachal Pradesh223634 Goa70420 Manipur6060 Puducherry57230 Nagaland3600 Meghalaya27121 Arunachal Pradesh310 Mizoram110 Sikkim100
Science 31 Mar 2020 Johnson & Johnso ...

Johnson & Johnson to begin coronavirus vaccine trials on humans in September

AFP
Published Mar 31, 2020, 6:03 pm IST
Updated Mar 31, 2020, 6:03 pm IST
US pharmaceutical Moderna has already moved into human trials for its vaccine candidate, as has China's CanSinoBIO.
Representative image of a vaccine being administered to a person. (Photo | US Air Force - Areca T Wilson)
 Representative image of a vaccine being administered to a person. (Photo | US Air Force - Areca T Wilson)

Washington: Johnson & Johnson has said it had selected a lead candidate vaccine for the new coronavirus that would move to human trials by September and could be ready for emergency use by early next year.

The pharmaceutical company has signed an agreement with the US government's Biomedical Advanced Research and Development Authority to invest USD 1 billion in the effort, it said in a statement on Monday.

 

J&J began working on the vaccine under investigation - Ad26 SARS-CoV-2 - in January using the same technology it used to develop a candidate vaccine for Ebola.

Paul Stoffels, the company's chief scientific officer, told AFP his team had combined a common cold virus incapable of replicating with parts of the coronavirus, and hoped it would trigger a human immune response.

"We had several vaccine candidates which we tested in animals in order to choose the best one, that took 12 weeks, from January 15 to today," he said.

They also had to evaluate which candidate vaccine could be upscaled, "to make sure on the one hand it works, and on the other hand, we can make a lot of it," he added.

Though there has never before been a successful human vaccine for any virus belonging to the coronavirus family, Stoffels said he was confident of achieving this milestone because J&J was working with the same team that had developed a candidate vaccine for SARS, which killed almost 800 people between 2002-2003.

The team's work was discontinued once the SARS outbreak was brought under control and interest was lost in bringing the vaccine to market.

"The question is, can you protect for infection or can you protect for severe disease? In many diseases, like in influenza, when you vaccinate on an annual basis, you protect for severe disease, you don't always protect for infection," said Stoffels.

J&J would also need to determine that the vaccine doesn't backfire and give people a higher chance of getting the disease.

The company said it was expanding its global manufacturing capacity both in the US and in other countries, to help it supply more than a billion doses of its vaccine around the world.

J&J is also working on antiviral treatments against the coronavirus.

Separately, the US pharmaceutical Moderna has already moved into human trials for its vaccine candidate, as has China's CanSinoBIO.

There are currently no approved vaccines or treatments for the disease.

Click on Deccan Chronicle Technology and Science for the latest news and reviews. Follow us on Facebook, Twitter

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT